SUSS MicroTec SE SMHN.DE
Quarterly and annual results for SUSS MicroTec stock (SMHN.DE) since 2023: revenue, earnings, balance sheet, cash flow and management guidance from IR documents, every figure with its source. As of 08/2026, quarterly reporting. Latest reading: Profitable on all levels.
Published by Michael Wirl · About us · Methodology
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
Business Model#
What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own.
SUSS MicroTec SE is a Germany-based manufacturer of specialized process equipment for semiconductor fabrication and microelectronic device production. Its portfolio spans lithography systems for wafer-level patterning, bonding and debonding tools for advanced packaging, wet processing equipment, and photomask processing systems, with customers including semiconductor manufacturers, memory chip producers, advanced packaging facilities, and photomask shops worldwide. Revenue is generated primarily through capital equipment sales, with the Photomask Solutions segment serving customers in photomask fabrication and growing exposure to demand from the AI chip module value chain and high-bandwidth memory applications.
Current Status#
Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number.
Price & Chart#
Interactive price chart (TradingView) and the trend of key figures from the core tables. The price chart loads only after a click; at that point a connection to TradingView is established.
Daily candles with news and earnings markers. Loads only on click.
Share-Price Drivers#
Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own.
Hybrid bonding solutions for HBM and AI chip modules are a named growth focus, with the XBC300 Gen2 D2W die-to-wafer platform launched and dedicated bonding products introduced, positioning the company in a demand pocket tied to AI-driven advanced packaging (12, 11)
XBC300 Gen2 D2W platform launched and D2W hybrid bonder introduced in 2025, an earlier BRIDG order for a hybrid bonding solution, and HBM/AI bonding solutions named as new products; gaining traction as a product line even as segment revenue was lower year-on-year (11, 6, 12)
Next-generation high-end EUVL photomask cleaner development, MaskTrack Smart Clean platform and next-generation MaskTrack SMART platform planned, with ASx 9500 mask cleaning solution; segment revenue lower year-on-year (3, 11, 9, 12)
GreenTec wafer cleaning solutions for 200mm and 300mm wafers and new cleaning platform for the mid-end segment (38-90 nm nodes) planned, broadening the cleaning portfolio (11, 9)
New Zhubei, Taiwan production facility leased and acquired in 2025, adding manufacturing capacity closer to key foundry customers (11, 10)
Recent quarterly revenue moved lower, with 116.2 million in 2026-Q2 after 141.7 million a year earlier, consistent with a decelerating growth flag (113)
Sector trend: Semiconductor equipment demand is uneven: advanced packaging and hybrid bonding for HBM and AI chips is expanding and drawing new product launches, while overall group revenue and margins have softened year-on-year with growth decelerating and guidance confirmed (12, 113).
Event Timeline#
This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Events are grouped by quarter (most recent first); the grey tag before each event names the event type, the date is the publication date of the source. Management quotes open the quarter block as direct quotes. Per quarter we show the three most defining events; more can be expanded per quarter, older years are collapsed. Every event carries its source as a superscript, clickable number.
2026 · 5 events
2026-Q1 · Jan – Mar 2026
Operating cash flow reached 25.7 EURm vs 10.6 EURm in 2025-Q1 (×2.4). 112
FY2025 sales of 503.2 million set a new company record, growing 12.6% year-on-year with both segments contributing double-digit growth 11
Full-year gross profit margin declined to 35.7% from 39.6% and EBIT margin to 13.1% from 16.7%, driven by ramp-up costs, Taiwan facility start-up, and less favorable product and customer mix 11
FY2026 guidance set with sales of €425-485 million and EBIT margin of 8-10%, reflecting subdued order intake and increased R&D spending; company described this as a lowering from prior-year actuals 11
2025 · 15 events
FY2025 · Jan – Dec 2025
2025-Q4 · Oct – Dec 2025
Operating income more than halved YoY (39.6 to 18.5 EURm, -53%). 113
Operating cash flow turned positive on a half-year basis (2025-H1: -16.3 to 2025-H2: +15.3 EURm, aggregated from reported quarters where needed). 113
2025-Q3 · Jul – Sep 2025
Guidance revised downward on October 27, 2025: gross profit margin lowered to 35-37% and EBIT margin to 11-13% 10
Order intake declined 14.3% year-to-date to €236.8 million, with Q3 marking an annual low at €70.0 million 10
Nine-month gross profit margin fell to 35.9% from 39.6%, with Advanced Backend Solutions gross margin declining to 34.3% from 41.6%, due to rework costs and unfavorable product mix 10
2025-Q2 · Apr – Jun 2025
H1 2025 gross profit margin contracted to 37.2% from 39.8%, below guidance, due to unfavorable product mix, Taiwan start-up costs, and inventory write-downs 9
Full-year gross profit margin guidance lowered to 37-39% from 39-41% and EBIT margin guidance lowered to 13-15% from 15-17% 9
MicroOptics business unit divestiture to Focuslight Technologies finalized with €3.4 million settlement agreed in Q2 2025 9
2025-Q1 · Jan – Mar 2025
Free cash flow improved to 8.9 million from negative €0.4 million in Q1 2024, driven by higher operating cash flow and lower inventory additions 8
Q1 2025 sales reached 124.9 million, driven by 47.0% growth in Advanced Backend Solutions, particularly Bonding Systems for AI chip modules 8
Company assumed operations at new Zhubei, Taiwan production site on April 1, 2025; tariff risks reassessed as high probability and severe impact 8
2024 · 15 events
FY2024 · Jan – Dec 2024
Operating income more than doubled YoY (27.8 to 74.6 EURm, +168%). 111
2024-Q3 · Jul – Sep 2024
Operating income more than doubled YoY (1.3 to 17.3 EURm, +1231%). 110
2024-Q2 · Apr – Jun 2024
Full-year 2024 guidance raised: sales target lifted to €380-410 million from €340-370 million, EBIT margin target to 14-16% from 10-12% 6
H1 2024 EBIT margin improved 6.9 percentage points to 15.6% from 8.7% in H1 2023 6
Launched fully integrated platform for die-to-wafer (D2W) and wafer-to-wafer (W2W) hybrid bonding processes in May 2024 6
2024-Q1 · Jan – Mar 2024
Net cash position expanded to 101.7 EURm from 29.6 EURm in 2023-Q3 (+244%, derived from reported financial debt minus cash). 108
EBIT rose from €3.8 million to 14.9, with EBIT margin expanding to 15.9% from 5.9% in the prior-year quarter 5
Sales of 93.5, described as the strongest first quarter in company history, up 46.1% year on year across both the Advanced Backend Solutions and Photomask Solutions segments 5
SUSS MicroOptics S.A. sold to Focuslight for €75.0 million total consideration, generating €58.3 million gain on disposal 5 6
Continuing operations sales grew 17.0% to €304.3 million; record order intake of €420.5 million, highest in company history, driven by AI chip demand for high-bandwidth memory bonding equipment 4
SUSS MicroOptics S.A. sold to Focuslight Technologies for €58.1 million, closing January 15, 2024; discontinued operations recorded a loss of €12.6 million in FY2023 4
FY2024 sales guidance of €340–370 million and gross margin of 35–38% announced; mid-term EBIT margin target of at least 15% by 2025 and sales target of €400 million confirmed 4
2023 · 12 events
2023-Q3 · Jul – Sep 2023
Q3 gross profit margin for continuing operations fell to 29.4% from 35.3% in Q3 2022 and EBIT margin to 1.9% from 8.9%, primarily due to China shipment delays and unfavorable product mix 2
Full-year 2023 revenue forecast for continuing operations cut again to €280–320 million from €320–340 million, driven by German export control documentation requirements causing China delivery delays since August 2023 2
MicroOptics division classified as discontinued operation as of September 30, 2023; sale of SUSS MicroOptics S.A. to Focuslight Technologies agreed November 8, 2023, with closing expected in Q1 2024 2
2023-Q2 · Apr – Jun 2023
Photomask Solutions sales more than doubled to €34.5 million, up 128.7% year-over-year, with order entry rising 35.3% to €84.7 million 3
H1 2023 gross profit margin declined to 33.8% from 35.1% year-over-year, negatively impacted 1.8 percentage points by MicroOptics division as customers reduced excess inventory built up in 2022 3
Full-year 2023 guidance cut: sales narrowed to €320–340 million, EBIT margin to 9–11%, gross margin to 35.5–37.5%, citing weak MicroOptics performance and inventory build 3
2023-Q1 · Jan – Mar 2023
Photomask Solutions division sales tripled from €7.8 million to €23.1 million driven by high order backlog and demand from Asia 1
Full-year 2023 guidance confirmed: sales €320–360 million, EBIT margin 10–12%, gross margin 37–38% 1
Lithography and Bonder divisions merged into new Advanced Backend Solutions division effective FY2023 1
Key Figures (€m)#
The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). Each row is one period, most recent first. Values with a dotted underline are clickable and show the raw value, the exact source location, the scale evidence and the source; derived values additionally show their formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Fiscal years
| Period | Revenue | Op. income | Net income | EPS (€) | OCF | Source |
|---|---|---|---|---|---|---|
| FY2025 | 503.2 | 65.9EBIT | 46.1 | 2.59 | -1 | 111 |
| FY2024 | 446.7 | 74.6EBIT | 110.3 | 2.70 | 33.5~ | 111 |
| FY2023 | – | 27.8EBIT | 4.7 | 0.91 | 12.5 | 104 |
Quarters
| Period | Published | Revenue | Op. income | Net income | EPS (€) | FCF | Cash | Net Debt | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-08-06 | 116.2 | 10.4° | 6.3 | 0.33 | – | 112.3 | -63.6~ | 113 |
| 2026-Q1* | 2026-05-07 | 86.5 | 3.8 | 2.5 | 0.13 | 23.2 | 120.9 | -72~ | 112 |
| 2025-Q4* | 2026-03-30 | 118.8 | 18.5 | 9.7 | 0.51*≈ | 5.6 | 98.7 | -49.1~ | 11 |
| 2025-Q3* | 2025-06-30 | 118 | 12.4EBIT | 9.2 | 0.48 | -0.7 | 94.4 | -43.9~ | 110 |
| 2025-Q2* | 2025-06-30 | 141.7 | 14.6~EBIT | 12.6~ | 0.66 | -36.4 | 99.2 | -43.3~ | 109 |
| 2025-Q1* | 2025-06-30 | 124.9 | 20.4~EBIT | 16.6 | 0.87 | 8.9 | 143.7 | -138.7 | 108 |
| 2024-Q4* | 2026-03-30 | 151.4 | 39.6 | 16.6 | 0.86*≈ | 1.1 | 136.2 | -130.9 | 109 |
| 2024-Q3* | 2025-06-30 | 102.5 | 17.3EBIT | 12.9 | 0.68≈ | 1.6 | – | -122.3 | 110 |
| 2024-Q2* | 2024-08-01 | 99.3 | 2.8~EBIT | 12.1 | 0.64≈ | – | 125.8 | -121 | 109 |
| 2024-Q1* | 2024-06-30 | 93.5 | 14.9EBIT | 68.7 | 0.54 | – | 108 | -101.7 | 108 |
| 2023-Q4* | 2024-03-18 | – | 25.1 | -5.1 | – | – | 38.1 | -32.8~ | 4 |
| 2023-Q3* | 2023-11-09 | 70 | 1.3EBIT | 0.4 | 0.02≈ | – | 38.9 | -29.6 | 2 |
| 2023-Q2* | 2023-08-02 | 62 | 0.7~EBIT | 4.1~ | 0.21≈ | – | 46.5 | -40.2~ | 3 |
| 2023-Q1* | 2023-06-30 | 70.4~ | 0.7~EBIT | 2.1 | 0.11 | 0.3 | 50.5 | -42.5 | 101 |
Balance Sheet & Cash Flow (€m)#
Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. Balance sheet values are as of the period end, flow items cover the period. Derived values are marked and are calculated, for example, as: net debt = financial debt − cash; free cash flow = operating cash flow − capex; the click popover shows formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.
Fiscal years
| Period | Published | Cash | Debt | Net Debt | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|
| FY2025 | 2026-03-30 | 98.7 | 4 | -49.1~ | -1 | 21.6 | -22.6 | 111 |
| FY2024 | 2026-03-30 | 136.2 | 5.3 | -130.9 | 33.5~ | 7.6 | 25.9~ | 111 |
| FY2023 | 2024-03-18 | 38.1 | 5.3~ | -32.8~ | 12.5 | 4.6 | 7.9 | 104 |
Quarters
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-08-06 | 112.3 | 3.4 | -63.6~ | – | -4.8 | – | – | 113 |
| 2026-Q1 | 2026-05-07 | 120.9 | 3.7 | -72~ | 4 | 25.7 | 2.5 | 23.2 | 112 |
| 2025-Q4 | 2026-03-30 | 98.7 | 4 | -49.1~ | – | 9.4 | 3.8 | 5.6 | 11 |
| 2025-Q3 | 2025-06-30 | 94.4 | 4.4 | -43.9~ | 6.5 | 5.9 | 6.6 | -0.7 | 110 |
| 2025-Q2 | 2025-06-30 | 99.2 | 4.7 | -43.3~ | – | -26.9 | 9.5 | -36.4 | 109 |
| 2025-Q1 | 2025-06-30 | 143.7 | 5 | -138.7 | 1.9 | 10.6 | 1.7 | 8.9 | 108 |
| 2024-Q4 | 2026-03-30 | 136.2 | 5.3 | -130.9 | – | 3.1 | 2.1 | 1.1 | 109 |
| 2024-Q3 | 2025-06-30 | – | – | -122.3 | 5.3 | 4.1 | 2.5 | 1.6 | 110 |
| 2024-Q2 | 2024-08-01 | 125.8 | – | -121 | – | 24.5 | 1.8 | – | 109 |
| 2024-Q1 | 2024-06-30 | 108 | 6.3 | -101.7 | 0.5 | 1.7 | 1.2 | – | 108 |
| 2023-Q4 | 2024-03-18 | 38.1 | 5.3~ | -32.8~ | – | 11.7 | 1 | – | 4 |
| 2023-Q3 | 2023-11-09 | 38.9 | 5.4 | -29.6 | 1.8 | -5.6 | 0.8 | – | 2 |
| 2023-Q2 | 2023-08-02 | 46.5 | 5.9~ | -40.2~ | 2.5 | 4.5 | 1.2 | – | 3 |
| 2023-Q1 | 2023-06-30 | 50.5 | 6.2 | -42.5 | 0.2 | 1.9 | 1.6 | 0.3 | 101 |
Revenue by Type (as of 2026-Q2 · EURm · 2/3)#
Revenue split by segment or product type, exactly as the company itself reports it. The basis is stated next to each value (3, 6 or 12 months); segment totals can deviate from group revenue (reconciliation/consolidation items). If the company changes its segment structure, older structures are kept in the expandable part. Rows in grey are no longer reported separately by the company; they show the last available figures and are never extrapolated.
| Segment | Since | Period | Basis | Revenue | Growth | Margin | Source |
|---|---|---|---|---|---|---|---|
| Advanced Backend Solutions | 2022-Q1 | 2026-Q1 | 3M | 55.7 | -30.7% | 32% | 12 |
| Photomask Solutions | 2022-Q1 | 2026-Q1 | 3M | 30.8 | -25.2% | 43.2% | 12 |
| MicroOptics | 2022-Q1 | FY2023 | 12M? | 22.9 | – | 10.6% | 4 |
Products & M&A (21/35 active+recent)#
Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. “Active/current” means: still mentioned in the most recent reports; what the company no longer mentions moves to the expandable part but is never deleted. Rows in grey are discontinued products.
| Product/Line | Since | Status | Source |
|---|---|---|---|
| UV projection scanner for square substrates (310 x 310 mm) | 2026 | Launched | 11 |
| New system solutions market launch | 2026 | Launched | 10 |
| New cleaning platform for mid-end segment (38-90 nm nodes) | 2026 | Launched | 9 |
| MaskTrack Smart Clean mask cleaning platform | 2026 | Launched | 11 |
| MaskTrack SMART platform next generation | 2026 | Launched | 9 |
| Mask aligner and UV projection scanner next generation (2x) | 2026 | Launched | 11 |
| ASx 9500 mask cleaning solution | 2026 | Launched | 11 |
| New site in Zhubei | 2025-12 | Launched | 12 |
| Four new product solutions | 2025-12 | Launched | 12 |
| New production site lease in Taiwan | 2025-04 | Launched | 11 |
| XBC300 Gen2 D2W die-to-wafer platform | 2025 | Launched | 11 |
| UV projection scanner increased production (2×) | 2025 | Launched | 11 |
| New cleaning solutions market launch for high-end and mid-end applications | 2025 | Launched | 11 |
| Modular surface preparation and cleaning solution for hybrid bonding | 2025 | Launched | 11 |
| Latest front-end lithography technology preparation | 2025 | Launched | 11 |
| Inkjet coating solutions | 2025 | Launched | 11 |
| Hybrid bonding solutions | 2025 | Launched | 11 |
| Advanced packaging expansion | 2025 | Launched | 11 |
| Die-to-wafer (D2W) hybrid bonder introduction (3×) | 2024-05 | Launched | 9 |
| Wafer cleaning solution (5×) | 2024 | Launched | 11 |
| High-bandwidth memory (HBM) bonding solutions for AI chip modules (3×) | 2023-12 | Launched | 12 |
| Received order from BRIDG for hybrid bonding solution in Q2 2024 | 2024-06 | Launched | 6 |
| New customer acquisitions for silicon carbide chip production on 200mm wafers | 2024-03 | Launched | 5 |
| International rollout of executive training program | 2024 | Launched | 4 |
| Expansion of temporary bonder manufacturing capacity at Hsinchu site | 2024 | Launched | 4 |
| Development of new photomask cleaning generation MaskTrack Smart | 2024 | Launched | 4 |
| Wafer cleaning technology pilot installation | 2023-12 | Launched | 4 |
| Next generation high-end EUVL photomask cleaner development | 2023-12 | Launched | 3 |
| Integrated D2W hybrid bonder prototype installation | 2023-12 | Launched | 3 |
| Hybrid bonding technology development | 2023-12 | Launched | 4 |
| New disruptive solution for cleaning wafers prototype installation | 2023-09 | Launched | 2 |
| Advanced Backend Solutions 300mm coater refinement and new 200mm coater generation launch | 2023-07 | Launched | 3 |
| Photomask Bake & Develop platform advancement to state of the art | 2023-06 | Launched | 3 |
| MicroOptics automotive lighting micro-optical headlight prototype and test system development | 2023-06 | Launched | 3 |
| AI chip capacity expansion orders for bonding equipment | 2023 | Launched | 4 |
M&A (8)#
All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Purchase prices appear only where the company itself has disclosed them. Rows in grey are cancelled transactions; the cancellation date is shown in the row.
Acquisitions
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Taiwan Zhubei production facility | 2025-10 | Completed | 11 |
| Zhubei production site (Taiwan) | 2025 | Completed | 11 |
| New production site in Zhubei, Taiwan | 2025 | Completed | 10 |
| Merging of Lithography and Bonder divisions | 2023-01 | Completed | 1 |
| Creation of Advanced Backend Solutions division | 2023-01 | Completed | 1 |
Divestitures / exits
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| MicroOptics business unit divestiture | 2024-01 | Divested | 11 |
| Divestiture of MicroOptics S.A. subsidiary (2×) | 2024-01 | Divested | 11 |
| Sale of SUSS MicroOptics S.A. to Focuslight (6×) | 2023-11 | Divested | 10 |
Reported KPIs (as disclosed) (154)#
Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. These “story KPIs” usually slip through standard databases; here they are collected as reported, with no calculation of our own. Important: the definition comes from the company itself and can differ from firm to firm; period and source are stated next to every value.
| Date | Period | KPI | Value / change | Source |
|---|---|---|---|---|
| 2026-03-30 | FY2025 | ROCE | 21.3% | 11 |
| 2026-03-30 | FY2025 | order intake | 354.3 (EUR in € million) | 11 |
| 2026-03-30 | FY2025 | order book | 266.8 million | 11 |
| 2026-03-30 | FY2025 | net working capital | 197.7 (EUR in € million) | 11 |
| 2026-03-30 | FY2025 | investment ratio | 4.6% | 11 |
| 2026-03-30 | FY2025 | gross profit margin 2025 | 35.7% | 11 |
| 2026-03-30 | FY2025 | gross profit margin | 35.7% | 11 |
| 2026-03-30 | FY2025 | equity ratio | 62.2% | 11 |
| 2026-03-30 | FY2025 | equity | 315.5 (EUR in € million) | 11 |
| 2026-03-30 | FY2025 | EBITDA margin | 15.4% | 11 |
| 2026-03-30 | FY2025 | EBIT margin | 13.1% | 11 |
| 2026-03-30 | FY2025 | contractual liabilities | 45.2 | 11 |
| 2026-03-30 | FY2025 | contractual assets | 58.7 (EUR in € million) | 11 |
| 2026-03-30 | FY2025 | yearly low (share price) (2024) | € 26.05 | 11 |
| 2026-03-30 | FY2025 | yearly low (share price) | € 24.04 | 11 |
| 2026-03-30 | FY2025 | yearly high (share price) (2024) | € 70.50 | 11 |
| 2026-03-30 | FY2025 | yearly high (share price) | € 53.00 | 11 |
| 2026-03-30 | FY2025 | Research and development costs | 47.0 (EUR millions) | 11 |
| 2026-03-30 | FY2025 | ROCE | 21.3% | 11 |
| 2026-03-30 | FY2025 | R&D ratio (2024) | 9.0% | 11 |
| 2026-03-30 | FY2025 | R&D ratio | 9.3% | 11 |
| 2026-03-30 | FY2025 | R&D expenditure (2024) | 40.0 | 11 |
| 2026-03-30 | FY2025 | R&D expenditure | 47.0 | 11 |
| 2026-03-30 | FY2025 | Price-earnings ratio (2024) | 8.5 | 11 |
| 2026-03-30 | FY2025 | Price-earnings ratio | 16.2 | 11 |
| 2026-03-30 | FY2025 | Photomask Solutions segment sales | 153.4 (EUR millions) | 11 |
| 2026-03-30 | FY2025 | Order intake (2024) | 423.7 (EUR millions) | 11 |
| 2026-03-30 | FY2025 | Order intake | 354.3 (EUR millions) | 11 |
| 2026-03-30 | FY2025 | Order book as of December 31 | 266.8 (EUR millions) | 11 |
| 2026-03-30 | FY2025 | Order book | € 266.8 million | 11 |
| 2026-03-30 | FY2025 | Opening price | € 48.85 | 11 |
| 2026-03-30 | FY2025 | Net Cash | 49.1 (EUR millions) | 11 |
| 2026-03-30 | FY2025 | Market capitalization (2024) | € 930.0 million | 11 |
| 2026-03-30 | FY2025 | Market capitalization | € 748.2 million | 11 |
| 2026-03-30 | FY2025 | Investment ratio | 4.6% | 11 |
| 2026-03-30 | FY2025 | Gross profit margin (2024) | 39.6% | 11 |
| 2026-03-30 | FY2025 | Gross profit margin | 35.7% | 11 |
| 2026-03-30 | FY2025 | Equity ratio | 62.2% | 11 |
| 2026-03-30 | FY2025 | Equity | 315.5 (EUR millions) | 11 |
| 2026-03-30 | FY2025 | EBITDA margin | 15.4% | 11 |
| 2026-03-30 | FY2025 | EBIT margin 2025 | 13.1% | 11 |
| 2026-03-30 | FY2025 | EBIT margin (2024) | 16.7% | 11 |
| 2026-03-30 | FY2025 | EBIT margin | 13.1% | 11 |
| 2026-03-30 | FY2025 | Depreciation | 11.8 | 11 |
| 2026-03-30 | FY2025 | Contract Assets | 58,669 (EUR in € thousand) | 11 |
| 2026-03-30 | FY2025 | Closing price (December 31) (2024) | € 48.65 | 11 |
| 2026-03-30 | FY2025 | Closing price (December 31) | € 39.14 | 11 |
| 2026-03-30 | FY2025 | Balance sheet total | 507.4 | 11 |
| 2026-03-30 | FY2025 | Average shares traded per day (XETRA) (2024) | 92,000 | 11 |
| 2026-03-30 | FY2025 | Average shares traded per day (XETRA) | 134,000 | 11 |
| 2026-03-30 | FY2025 | Average XETRA trading volume per day (2024) | € 4.6 million | 11 |
| 2026-03-30 | FY2025 | Average XETRA trading volume per day | € 4.8 million | 11 |
| 2026-03-30 | FY2025 | Advanced Backend Solutions segment sales | 349.7 (EUR millions) | 11 |
| 2026-05-07 | 2025-H2 | Order book | 330.1 (EUR in Mio. €) | 12 |
| 2026-05-07 | 2025-H2 | Net cash | 72.0 (EUR in Mio. €) | 12 |
| 2026-05-07 | 2025-H2 | Gross profit margin | 36.1% | 12 |
| 2026-05-07 | 2025-H2 | Free cash flow | 23.2 (EUR in Mio. €) | 12 |
| 2026-05-07 | 2025-H2 | Equity ratio | 60.7% | 12 |
| 2026-05-07 | 2025-H2 | EBITDA margin | 8.9% | 12 |
| 2026-05-07 | 2025-H2 | EBIT margin | 4.3% | 12 |
| 2025-11-05 | 2025-Q3 | order book | 276.1 (EUR in € million) | 10 |
| 2025-11-05 | 2025-Q3 | Net cash | 43.9 (EUR in € million) | 10 |
| 2025-11-05 | 2025-Q3 | gross profit margin | 35.9% | 10 |
| 2025-11-05 | 2025-Q3 | equity ratio | 58.2% | 10 |
| 2025-11-05 | 2025-Q3 | EBITDA margin | 16.0% | 10 |
| 2025-11-05 | 2025-Q3 | EBIT margin | 14.1% | 10 |
| 2025-07-22 | 2025-H1 | R&D ratio | 8.8% | 9 |
| 2025-07-22 | 2025-H1 | Order book | 325.8 (EUR in € million) | 9 |
| 2025-07-22 | 2025-H1 | Net cash | 43.3 (EUR in € million) | 9 |
| 2025-07-22 | 2025-H1 | Gross profit margin | 37.2% | 9 |
| 2025-07-22 | 2025-H1 | Equity ratio | 55.8% | 9 |
| 2025-07-22 | 2025-H1 | Equity | 297.5 (EUR in € million) | 9 |
| 2025-07-22 | 2025-H1 | EBITDA margin | 17.2% | 9 |
| 2025-07-22 | 2025-H1 | EBIT margin | 15.7% | 9 |
| 2025-07-22 | 2025-H1 | Capital expenditure ratio | 4.2% | 9 |
| 2025-05-05 | 2025-Q1 | R&D ratio | 8.8 % | 8 |
| 2025-05-05 | 2025-Q1 | Order book | 392.7 (EUR in € million) | 8 |
| 2025-05-05 | 2025-Q1 | Gross profit margin | 37.9 % | 8 |
| 2025-05-05 | 2025-Q1 | Equity ratio | 57.1 % | 8 |
| 2025-05-05 | 2025-Q1 | Equity | 292.9 (EUR in € million) | 8 |
| 2025-05-05 | 2025-Q1 | EBIT margin | 16.6 % | 8 |
| 2025-05-05 | 2025-Q1 | Balance sheet total | 513.4 | 8 |
| 2024-08-01 | 2024-Q2 | R&D % of sales | 9.6% | 6 |
| 2024-08-01 | 2024-Q2 | R&D expenses H1 | 18.6 (EUR millions) | 6 |
| 2024-08-01 | 2024-Q2 | Order book prior year | 381.5 (EUR millions) | 6 |
| 2024-08-01 | 2024-Q2 | order book | 450.0 (EUR millions) | 6 |
| 2024-08-01 | 2024-Q2 | Gross profit margin Q2 | 40.5% | 6 |
| 2024-08-01 | 2024-Q2 | Gross profit margin H1 | 39.8% | 6 |
| 2024-08-01 | 2024-Q2 | equity ratio | 56.0% | 6 |
| 2024-08-01 | 2024-Q2 | EBITDA margin Q2 | 17.2% | 6 |
| 2024-08-01 | 2024-Q2 | EBITDA margin H1 | 17.5% | 6 |
| 2024-08-01 | 2024-Q2 | EBIT margin Q2 | 15.3% | 6 |
| 2024-08-01 | 2024-Q2 | EBIT margin H1 | 15.6% | 6 |
| 2024-08-01 | 2024-Q2 | Book-to-bill ratio | 1.00 | 6 |
| 2024-08-01 | 2024-Q2 | Asia Pacific sales % | 88.8% | 6 |
| 2024-08-01 | 2024-Q2 | Asia Pacific order intake % | 75.6% | 6 |
| 2024-05-06 | 2024-Q1 | ROCE | 7.8 | 5 |
| 2024-05-06 | 2024-Q1 | Order book | 456.9 (EUR in € million) | 5 |
| 2024-05-06 | 2024-Q1 | Gross profit margin | 39.1% | 5 |
| 2024-05-06 | 2024-Q1 | Equity ratio | 58.0% | 5 |
| 2024-05-06 | 2024-Q1 | EBITDA margin | 17.9% | 5 |
| 2024-05-06 | 2024-Q1 | EBIT margin | 15.9% | 5 |
| 2024-05-06 | 2024-Q1 | Book-to-bill ratio | 1.05 | 5 |
| 2024-03-18 | FY2023 | ROCE continuing | 17.5% | 4 |
| 2024-03-18 | FY2023 | ROCE | 8.3% | 4 |
| 2024-03-18 | FY2023 | R&D expenditures | 31,309 | 4 |
| 2024-03-18 | FY2023 | Personnel expenses | 95,580 (EUR in € thousand) | 4 |
| 2024-03-18 | FY2023 | order intake | € 420.5 million | 4 |
| 2024-03-18 | FY2023 | Order book prior year | 335,361 (EUR in € thousand) | 4 |
| 2024-03-18 | FY2023 | Order book Dec 31 | 464.5 (EUR in € million) | 4 |
| 2024-03-18 | FY2023 | order book | € 452.5 million | 4 |
| 2024-03-18 | FY2023 | Investment ratio continuing | 1.5% | 4 |
| 2024-03-18 | FY2023 | investment ratio | 2.5% | 4 |
| 2024-03-18 | FY2023 | Gross profit margin continuing | 34.1% | 4 |
| 2024-03-18 | FY2023 | gross profit margin | 32.4% | 4 |
| 2024-03-18 | FY2023 | equity ratio | 47.8% | 4 |
| 2024-03-18 | FY2023 | EBITDA margin continuing | 11.4% | 4 |
| 2024-03-18 | FY2023 | EBITDA margin | 7.8% | 4 |
| 2024-03-18 | FY2023 | EBIT margin continuing | 9.1% | 4 |
| 2024-03-18 | FY2023 | EBIT margin | 4.9% | 4 |
| 2024-03-18 | FY2023 | Cost of materials | 129,589 (EUR in € thousand) | 4 |
| 2024-03-18 | FY2023 | Contract liabilities | 87,038 | 4 |
| 2024-03-18 | FY2023 | Contract assets | 35,238 (EUR in € thousand) | 4 |
| 2024-03-18 | FY2023 | Total equity prior year | 177,730 (EUR in € thousand) | 4 |
| 2024-03-18 | FY2023 | Total equity | 176,500 (EUR in € thousand) | 4 |
| 2024-03-18 | FY2023 | Research and development costs | 31.3 (EUR thousands) | 4 |
| 2024-03-18 | FY2023 | ROCE | 17.5% | 4 |
| 2024-03-18 | FY2023 | Order book as of December 31 | 452.5 (EUR thousands) | 4 |
| 2024-03-18 | FY2023 | Investment ratio | 1.5% | 4 |
| 2024-03-18 | FY2023 | Gross profit margin | 34.1% | 4 |
| 2024-03-18 | FY2023 | Gross profit | 103.9 (EUR thousands) | 4 |
| 2024-03-18 | FY2023 | Equity ratio prior year | 50.3% | 4 |
| 2024-03-18 | FY2023 | Equity ratio | 47.7% | 4 |
| 2024-03-18 | FY2023 | Equity | 176.6 (EUR thousands) | 4 |
| 2024-03-18 | FY2023 | EBITDA margin | 11.4% | 4 |
| 2024-03-18 | FY2023 | EBIT margin | 9.1% | 4 |
| 2024-03-18 | FY2023 | Depreciation | 6.9 | 4 |
| 2024-03-18 | FY2023 | Cost of sales | 200.4 (EUR thousands) | 4 |
| 2024-03-18 | FY2023 | Balance sheet total | 369.7 | 4 |
| 2023-11-09 | 2023-Q3 | Order backlog | 414.7 (EUR in € million) | 2 |
| 2023-11-09 | 2023-Q3 | Book-to-bill ratio | 1.4 | 2 |
| 2023-08-02 | 2023-Q2 | Order backlog | 389.8 (EUR in EUR million) | 3 |
| 2023-08-02 | 2023-Q2 | investment ratio | 3.7% | 3 |
| 2023-08-02 | 2023-Q2 | gross profit margin | 33.8% | 3 |
| 2023-08-02 | 2023-Q2 | equity ratio | 49.2% | 3 |
| 2023-08-02 | 2023-Q2 | EBITDA margin | 9.2% | 3 |
| 2023-08-02 | 2023-Q2 | EBIT margin | 5.8% | 3 |
| 2023-08-02 | 2023-Q2 | Book-to-bill ratio | 1.3 | 3 |
| – | 2023-Q1 | Order backlog | 373.2 (EUR in € million) | 1 |
| – | 2023-Q1 | Net cash | 41.0 (EUR in € million) | 1 |
| – | 2023-Q1 | Investment ratio | 2.2% | 1 |
| – | 2023-Q1 | Gross profit margin | 33.1% | 1 |
| – | 2023-Q1 | Equity ratio | 51.6% | 1 |
| – | 2023-Q1 | EBIT margin | 4.1% | 1 |
Guidance Tracking (latest per metric/period · 9/15)#
All management forecasts (guidance) and their later outcome. Types: fiscal-year targets as well as quarterly/half-year targets; per metric and period the most recent statement applies, older versions can be expanded. The status is checked automatically against the actuals reported later: open (period still running), met, beaten, missed. For ranges (“X to Y”) reaching the range counts. Logged neutrally, no estimate of our own, no assessment.
Actuals: revenue in €m · ratios in %
| For period | Guided on | Metric | Guided | Actual | Verdict | Direction | Source |
|---|---|---|---|---|---|---|---|
| FY2030 | 2026-03-30 | Revenue | 750–900 | – | pending | initiated | 11 |
| FY2030 | 2026-03-30 | Gross margin (GAAP) | 43–45% | – | pending | initiated | 11 |
| FY2030 | 2026-03-30 | EBIT margin | 20–22% | – | pending | initiated | 11 |
| FY2026 | 2026-03-30 | Revenue | 425–485 | – | pending | confirmed | 12 |
| FY2026 | 2026-03-30 | Gross margin (GAAP) | 35–37% | – | pending | confirmed | 12 |
| FY2026 | 2026-03-30 | EBIT margin | 8–10% | – | pending | confirmed | 12 |
| FY2025 | 2025-11-05 | Gross margin (GAAP) | 35–37% | – | – | cut | 10 |
| FY2025 | 2025-11-05 | EBIT margin | 11–13% | 13.1 | beat | cut | 10 |
| FY2025 | 2025-05-05 | Revenue | 470–510 | 503.2 | in line | confirmed | 10 |
| FY2024 | 2024-08-01 | Revenue | 380–410 | 446.7 | beat | raised | 6 |
| FY2024 | 2024-08-01 | Gross margin (GAAP) | 38–40% | – | – | raised | 6 |
| FY2024 | 2024-08-01 | EBIT margin | 14–16% | 16.7 | beat | raised | 6 |
| FY2023 | 2023-11-09 | Revenue | 300–340 | – | – | cut | 2 |
| FY2023 | 2023-11-09 | Gross margin (GAAP) | 32–34% | – | – | cut | 2 |
| FY2023 | 2023-11-09 | EBIT margin | 4–8% | – | – | cut | 2 |
Development#
A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Most recent period first, grouped by year; each text is written from the original report of that period, superscript numbers lead to the source.
FY2025
SUSS MicroTec SE set a new sales record in FY2025 with revenue of 503.2 million, a 12.6% increase year-on-year, as both the Advanced Backend Solutions and Photomask Solutions segments delivered double-digit growth 11. Gross profit margin declined to 35.7% from 39.6% and EBIT margin fell to 13.1% from 16.7%, reflecting production ramp-up costs at the new Zhubei, Taiwan facility, an unfavorable product and customer mix, and one-off capacity expansion effects 11. Free cash flow from continuing operations was negative at 22.6 million compared with positive €25.0 million in 2024, driven by a significant working capital build-up and investments in the Taiwan production site 11. Order intake declined to €354.3 million from €423.7 million, primarily due to reduced orders from Chinese customers in the Photomask Solutions segment, leaving the order book at €266.8 million at year-end 11. At the annual results, management introduced the Ambition 2030 strategic framework targeting sales of €750-900 million and an EBIT margin of 20-22%, while initial FY2026 guidance pointed to sales of €425-485 million and an EBIT margin of 8-10%, reflecting the reduced order backlog and higher planned R&D investment 11.
FY2024
SUSS MicroTec SE reported full-year 2024 revenue of 446.7 and operating income of 74.6 111. Net income of 110.3 111 was materially elevated by a €58.3 million gain on disposal arising from the sale of SUSS MicroOptics S.A. to Focuslight on January 15, 2024 for total consideration of €75.0 million 5 6. The first quarter was described as the strongest in the company's history at 93.5, with sales up 46.1% year on year driven by growth in both the Advanced Backend Solutions and Photomask Solutions segments 5. Full-year 2024 guidance was raised on July 18, 2024, lifting the sales target from €340-370 million to €380-410 million 6. The company ended the year with a net cash position of 130.9 and full-year free cash flow of 25.9 111.
FY2023
SUSS MicroTec SE's continuing operations recorded sales of €304.3 million in FY2023, 17.0% above the prior year, while order intake reached a record €420.5 million, the highest in company history, supported by demand for bonding equipment used in AI chip production 4. Gross profit margin declined to 34.1% from 38.7% and EBIT margin fell to 9.1% from 12.1%, reflecting capacity expansion costs and delivery disruptions caused by German export control measures on shipments to China from August 2023 onwards 4. The MicroOptics division was classified as a discontinued operation at the end of Q3 following an agreement to sell SUSS MicroOptics S.A. to Focuslight Technologies; discontinued operations contributed a loss of €12.6 million to the full-year result, leaving total net income at 4.7 4. Full-year free cash flow from continuing operations was 7.9, with the order book reaching €452.5 million as of December 31, 2023 4.
Glossary#
- Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
- Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Sources: official investor relations documents#
All original documents used, with type (e.g. quarterly, half-year, annual report), publication date and a direct link to the filing (EDINET/SEC/IR). Every superscript number in the report points to an entry in this list; so every figure can be traced back to its place in the original.
| # | Document type | Published | Link |
|---|---|---|---|
| #1 / #101 | IR-Quarter | – | Open |
| #5 / #105 | IR-Quarter | – | Open |
| #7 | IR-Quarter | – | Open |
| #8 / #108 | IR-Quarter | – | Open |
| #9 / #109 | IR-Half | – | Open |
| #10 / #110 | IR-Quarter | – | Open |
| #3 / #103 | IR-Quarter | 2023-08-02 | Open |
| #2 / #102 | IR-Quarter | 2023-11-09 | Open |
| #4 / #104 | IR-Annual | 2024-03-18 | Open |
| #6 / #106 | IR-Quarter | 2024-08-01 | Open |
| #11 / #111 | IR-Annual | 2026-03-30 | Open |
| #12 / #112 | IR-Half | 2026-05-07 | Open |
| #113 | IR-Half | 2026-08-06 | Open |
FAQ#
Is there a management forecast (guidance) for FY2030?
Yes. Management has issued targets for FY2030, including Revenue. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Where can I find the official investor relations documents of SUSS MicroTec SE?
The sources chapter links all 24 original filings used (IR documents) with type, publication date and a direct link; every figure in the report carries a source number.